Home › NDC Lookup › RxCUI directory › RxCUI 1433736

Naftifine hydrochloride 0.02 MG/MG Topical Gel [Naftin] — RxCUI 1433736

Name: Naftifine hydrochloride 0.02 MG/MG Topical Gel [Naftin] (RxCUI 1433736)
Creator: Brian Staiger, PharmD

RxNorm drug concept · Semantic branded drug

RxCUI 1433736 Semantic branded drug · SBD ● Current RxNorm concept 2 FDA products 4 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by Dr. Brian Staiger, PharmD

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI1433736

Official nameNaftifine hydrochloride 0.02 MG/MG Topical Gel [Naftin]

Concept typeSemantic branded drug (SBD)

RxNorm statusCurrent RxNorm concept

Also known asNaftin 2 % Topical Gel; Naftin 0.02 MG/MG Topical Gel

FDA products mapped2

Package NDCs mapped4

Reported Medicaid activity (SDUD)551 prescriptions · 1 state & territory Medicaid programs · latest period Q4 2025

RxNorm release07/06/2026

Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Naftifine Topical: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist

Naftifine is an antifungal medicine applied to the skin to treat common fungal infections. The gel form (2%) is specifically approved for athlete's foot between the toes — that itc...
What exactly is naftifine used to treat?
Apply a thin layer once a day to the infected area plus a small border — about a half-inch — of the healthy skin around it. Treatment generally lasts 2 weeks. It's important to fin...
How do I apply it, and how long do I need to use it?

📖 Read our full Naftifine Topical guide →

🕸️ Concept Web — How Naftifine hydrochloride 0.02 MG/MG Topical Gel [... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.

This page's concept Naftifine hydrochloride 0.02 MG/MG Topical Gel [Naftin] RxCUI 1433736 Semantic branded drug · SBD

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

Ingredients 2

The active substance itself — no strength, form, or brand attached yet.
- Naftifine 31476 IN
- Naftifine hydrochloride 91293 PIN
Brand names 1

The same medicine's trade names. A brand name alone says nothing about strength or form.
- Naftin 218564 BN
Dose forms 9

The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
- Naftifine Topical Gel 487271 SCDF
- Naftifine hydrochloride Topical Gel 2647550 SCDFP
- Naftifine Topical Product 1158381 SCDG
- Naftifine hydrochloride Topical Product 2660562 SCDGP
- Naftifine Topical Gel [Naftin] 370393 SBDF
- Naftifine hydrochloride Topical Gel [Naftin] 2654709 SBDFP
- Naftin Topical Product 1177534 SBDG
- Topical Gel 346286 DF
- +1 more in this family
Clinical & branded drugs 3

Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
- Naftifine hydrochloride 0.02 MG/MG Topical Gel 1433734 SCD
- Naftifine hydrochloride 0.02 MG/MG 1433733 SCDC
- Naftifine hydrochloride 0.02 MG/MG [Naftin] 1433735 SBDC

Showing up to 8 concepts per family — 14 of 15 stored related concepts drawn.

These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

Naftifine hydrochloride 0.02 MG/MG Topical Gel SCD · 1433734
Naftifine hydrochloride 0.02 MG/MG SCDC · 1433733
Naftifine Topical Gel SCDF · 487271
Naftifine hydrochloride Topical Gel SCDFP · 2647550
Naftifine Topical Product SCDG · 1158381
Naftifine hydrochloride Topical Product SCDGP · 2660562

Brand-Name Concepts

Naftifine hydrochloride 0.02 MG/MG [Naftin] SBDC · 1433735
Naftifine Topical Gel [Naftin] SBDF · 370393
Naftifine hydrochloride Topical Gel [Naftin] SBDFP · 2654709
Naftin Topical Product SBDG · 1177534
Naftin BN · 218564

📦 FDA Products & Package NDCs

2 products · 4 package NDCs

4 package NDCs map to RxCUI 1433736 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.

Package NDC	Package	Brand / generic name	Labeler	Marketing start
54766-0772-45	1 TUBE in 1 CARTON (54766-772-45) / 45 g in 1 TUBE	Naftin	Sebela Pharmaceuticals Inc.	2018-03-01
54766-0772-60	1 TUBE in 1 CARTON (54766-772-60) / 60 g in 1 TUBE	Naftin	Sebela Pharmaceuticals Inc.	2018-03-01
83107-0023-45	1 TUBE in 1 CARTON (83107-023-45) / 45 g in 1 TUBE	Naftin	Legacy Pharma USA Inc.	2025-07-29
83107-0023-60	1 TUBE in 1 CARTON (83107-023-60) / 60 g in 1 TUBE	Naftin	Legacy Pharma USA Inc.	2025-07-29

Observed labelers: Legacy Pharma USA Inc. (2) · Sebela Pharmaceuticals Inc. (2) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

💲 Pricing (NADAC)

NADAC is CMS's National Average Drug Acquisition Cost — roughly what pharmacies pay to buy the drug. It is an acquisition benchmark, not your copay.

Per gm · median

$10.8993

Range $10.8738–$10.9247 · middle 50% $10.8738–$10.9247 · 4 NDCs

Latest compatible distributions from the CMS NADAC file · dataset watermark 2026-07-10. Prices vary by package and pharmacy; a distribution is shown instead of one misleading number. Rows the dataset is silent on carry no price. No zero-cost conclusion should be drawn.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7

openFDA export observedJul 14, 2026

RxNorm release07/06/2026

Methodology2026-07-full-catalog-v1

A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.

This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.